DAWN Stock Analysis: Buy, Sell, or Hold?
DAWN - Day One Biopharmaceuticals, Inc. Common Stock
$21.53
0.04 (0.19%)
▲
5d:
+0.28%
30d:
+0.8%
90d:
+78.38%
BUY
MODERATE Confidence
Analysis Updated: Apr 22, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When DAWN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DAWN shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: DAWN shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: DAWN is currently trading at $21.53, which is considered extended relative to its 30-day fair value range of $21.46 to $21.50. From a valuation perspective, the stock is trading at a discount (Forward PE: -504.2) compared to its historical average (73.7). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, DAWN is in a strong uptrend. The price is currently testing key support at $21.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DAWN is in a strong uptrend. The price is currently testing key support at $21.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$21.46 -
$21.50
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.4%
Protect Your Profits
DAWN is technically overbought (RSI 80). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($21.50)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$21.46 -
$21.50
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.36
(1.7%)
Support & Resistance Levels
Support Level
$21.45
Resistance Level
$21.53
Current Trend
Strong Uptrend
Technical data as of
Apr 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-504.22
Wall Street Target
$21.50
(-0.1%)
Revenue Growth (YoY)
83.9%
Profit Margin
-67.8%
PE vs Historical
-504.2 vs 73.7
CHEAP
Share & Embed Analysis
Last updated: May 22, 2026 2:20 AM ET
Data refreshes hourly during market hours. Next update: 3:20 AM
Data refreshes hourly during market hours. Next update: 3:20 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DAWN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Charles N York II
SELL
6065 shares
2026-02-17
Jeremy Bender
SELL
15459 shares
2026-02-17
Lauren Merendino
SELL
5814 shares
2026-02-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$55 | 57 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 51 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$242 | 63 BUY |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$118 | 55 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 52 HOLD |
Advanced DAWN Option Strategies
Professional options setups generated by AI based on today's DAWN price and gamma walls.
